Up Close and Personal with the CEO & Founder of Foresite Capital Jim Tananbaum

Jim Tananbaum is the CEO and Founder of Foresite Capital. He founded Foresite back in 2011 as a private equity firm dedicated to healthcare and specializing in the identification of emerging healthcare leaders. His firm helps emerging healthcare leaders grow to profitability by supplying them with information, networks, and capital.

Before founding Foresite Capital, Mr. Jim Tananbaum co-founded two healthcare investment practices and two biopharmaceutical companies. Jim founded GelTex Pharmaceuticals, which for not more than $80 million introduced two drugs on to the market. In 1998, GelTex was acquired for approximately $1.6 billion when Renagel (Renzela), its lead drug attained an annual run rate revenue of over $200 million. Presently, Renzela is approximated to produce about $1 billion in revenue annually. He also co-founded Theravance, Inc and held the position of CEO.

Mr. Tananbaum’s investment experience is very vast, reveals Medium.com. He is Prospect Venture Partners II & III’s founding partner. Additionally, he helped Sierra Ventures set up its healthcare investment practice services. He has led several investments such as the Amerigroup NASDAQ: AMGP, Amira Pharmaceuticals, Jazz Pharmaceuticals NASDAQ: JAZZ, and Healtheon NASDAQ:WBMD. When founding Foresite Capital, Jim had the vision of bringing together all elements of his career to come up with a novel investment platform.

At Yale, Jim was an electrical engineering and math major. He received his MBA and MD from Harvard. He also holds an MS from the Massachusetts Institute of Technology. Ever since Jim was in high school, he has been zealous about the marriage of computer science and interdisciplinary hard sciences with healthcare. Jim has had quite a number of long-term productive relationships with various leading academicians.

His collaborators including George Whitesides (Harvard), Roy Vagelos (Merck and Theravance), Rick Klausner (NCI), Rick Levin (Yale), and Bob Gunderson (Gunderson Detmer) have been his mentors. Mr. Tananbaum is passionate about carrying on with his evolution of working on fields with leading academicians and entrepreneurs.

According to Jim Tananbaum, bringing ideas to life doesn’t involve capital only. It requires engaging the most effective, smartest, and persistent leaders in healthcare. His business involves providing these people with means to aid in their critical scientific discoveries.

https://ideamensch.com/jim-tananbaum/

Mikhail Blagosklonny: Modern Breakthrough in Oncology

Mikhail Blagosklonny and oncology are the same. Mikhail has been practicing oncology for many years, and as long as most people can remember. Therefore, Blagosklonny has become a real expert in the field. Blagosklonny’s journey to oncology started ages ago when Mikhail enrolled to the First Pavlov State Medical University of St. Petersburg in pursuit of an MD in Internal Medicine and a Ph.D. in Experimental Medicine and Cardiology. Ever since graduating from school, a light has been shining on the life of Mr. Blagosklonny. Through his education, Mikhail has been able to get decent employment in institutions like the New York Medical College, Ordway Research Institute, Roswell Park Cancer Institute, and Oncotarget. Visit classroomvoices.org to read more about Mikhail.

While working in the organizations mentioned above, Mikhail has been able to gain extensive experience, skills, and expertise that has made him be the best there is in the field of oncology. As a university professor, Mr. Blagosklonny has been able to come up with personal theories, but none stands out like the one in which he proposes that TOR Signaling can be made use of to control cancer and aging. Mikhail believes that Rapamycin can be utilized to treat lie extension. Although his hypothesis is relatively new, Mikhail has been doing extensive research on ontogenesis, cell cycle, mitosis, drug resistance, apoptosis, tumor suppressors, and anti-cancer therapeutics. Mikhail also believes that Rapamycin can also help heal people suffering from cancer. Previous studies show that Rapamycin is ideal for the elderly since it helps boost their immunity. Based on the test results that Mikhail found during his research, he has been extremely passionate about pushing for the use of Rapamycin since he has a conviction that Rapamycin is the new drug to aging and cancer.

Because Mikhail Blagosklonny is an individual that is well educated, he has been able to author the Aging Hyperfunction Theory. In his lifetime, Mikhail has also written 300 articles that center on cellular biology, molecular biology, and clinical investigations. Blagosklonny has also written book chapters and reviews, with all of his written works having undergone publishing. Mr. Mikhail Blagosklonny has also contributed a lot of knowledge to the world through the International Knowledge of Cancer and the American Journal of Pathology. Since Mikhail has been a significant contributor to cellular experience, he is regarded to be one of the best researchers when it comes to Oncology. Mikhail lives a purpose driven life and is motivated to see to it that the world gets saved from all manner of diseases. Blagosklonny believes that human life is sacred and should, therefore, be protected at all costs. If his findings stand to be true, Mikhail Blagosklonny will get what he has always dreamt of in life, and that is a disease free society. Through his cure, the process of aging will be slowed down thus giving you much opportunity to enjoy a young life. Therefore, Mikhail’s findings might bear us a lot of fruit in the long run if the results of his research prove to be worthwhile.

Follow: https://www.linkedin.com/in/mikhail-blagosklonny-91abb531